Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study

Overview of attention for article published in Frontiers in oncology, August 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,664 followers.

RT @FrontOncology: New research: Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred p…

01 Sep 2023

Reply Repost Favourite

New research: Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study: Background Microsatellite stable (MSS)… #oncology https://t.

01 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.